Lipin-1, a mammalian phosphatidic acid phosphatase (PAP), has recently emerged as a key regulator involved in various signaling pathways in lipid metabolism via its function as a PAP enzyme in the triglyceride synthesis pathway and in the nucleus as a transcriptional regulator. Prior to the identification of lipin-1 in 2001, ethanol- mediated activation of hepatic PAP activity was shown to be closely associated with the development of liver steatosis in rodents and humans. However, there is little knowledge of the molecular mechanisms and signaling pathways affected by ethanol, which result in altering the gene and protein expression of lipin-1 and its functions in liver. Therefore, the objective of the current proposal is to test the hypothesis that chronic ethanol exposure may significantly impair the functional activity of lipin-1 in the liver. Such impairment may lead to derangement of hepatic lipid metabolism, thereby contributing to increased hepatic lipid synthesis, reduced oxidation, and suppressed VLDL secretion, and ultimately liver steatosis. We will use state-of-the-art molecular, cellular, and biochemical approaches, unique hepatic cell culture and genetically modified mice models to test our hypotheses. The two Specific Aims of the proposal are to: (1) Investigate the role of lipin-1 in the development of alcoholic fatty liver in mice; (2) Identify the mechanisms through which ethanol causes lipin-1 Hyper-acetylation/Hypo-SUMOylation, reduces nuclear localization of Lipin-1 and impairs nuclear Lipin- 1 co-transcriptional activity in cultured hepatic cells and in mice. The studies carried out within these proposed Specific Aims will facilitate the development of nutritional or pharmacological agents to target Lipin-1 and its signaling pathways in treating human AFLD. The proposed studies presented here are also expected to shed light on the molecular mechanisms underlying both AFLD and NAFLD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Specialized Center (P50)
Project #
5P50AA024333-05
Application #
9900709
Study Section
Special Emphasis Panel (ZAA1)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Dasarathy, Srinivasan; Hatzoglou, Maria (2018) Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care 21:30-36
Lindenmeyer, Christina C; McCullough, Arthur J (2018) The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis 22:11-21
Manterola, Andrea; Bernal-Chico, Ana; Cipriani, Raffaela et al. (2018) Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. Biochem Pharmacol 157:189-201
McCullough, Rebecca L; McMullen, Megan R; Poulsen, Kyle L et al. (2018) Anaphylatoxin Receptors C3aR and C5aR1 Are Important Factors That Influence the Impact of Ethanol on the Adipose Secretome. Front Immunol 9:2133
Chen, Li; Chen, Ruju; Kemper, Sherri et al. (2018) Pathways of production and delivery of hepatocyte exosomes. J Cell Commun Signal 12:343-357
McCullough, Rebecca L; McMullen, Megan R; Sheehan, Megan M et al. (2018) Complement Factor D protects mice from ethanol-induced inflammation and liver injury. Am J Physiol Gastrointest Liver Physiol 315:G66-G79
Schugar, Rebecca C; Willard, Belinda; Wang, Zeneng et al. (2018) Postprandial gut microbiota-driven choline metabolism links dietary cues to adipose tissue dysfunction. Adipocyte 7:49-56
Brown, J Mark; Hazen, Stanley L (2018) Microbial modulation of cardiovascular disease. Nat Rev Microbiol 16:171-181
You, Min (2018) Obesity and Binge Drinking: Two Hits Driving Liver Fibrosis Progression? Cell Mol Gastroenterol Hepatol 5:424-425
You, Min; Zhou, Zhou; Daniels, Michael et al. (2018) Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury. Gene Expr 18:103-113

Showing the most recent 10 out of 42 publications